What is HC Wainwright’s Forecast for SPRB FY2025 Earnings?

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Spruce Biosciences in a research report issued on Monday, December 22nd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($57.15) for the year. HC Wainwright has a “Buy” rating and a $220.00 price target on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2025 earnings at ($14.95) EPS, Q1 2026 earnings at ($12.15) EPS, Q2 2026 earnings at ($10.30) EPS, Q3 2026 earnings at ($9.16) EPS, Q4 2026 earnings at ($1.69) EPS and FY2026 earnings at ($32.93) EPS.

Spruce Biosciences (NASDAQ:SPRB) last announced its quarterly earnings results on Monday, November 10th. The company reported ($14.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($15.56) by $0.98.

Several other equities analysts have also recently commented on SPRB. Citigroup reissued a “market perform” rating on shares of Spruce Biosciences in a research note on Tuesday, November 11th. Oppenheimer started coverage on shares of Spruce Biosciences in a research note on Tuesday. They set an “outperform” rating and a $283.00 price objective on the stock. JMP Securities set a $259.00 price objective on Spruce Biosciences in a report on Tuesday, November 11th. Leerink Partnrs upgraded Spruce Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 3rd. Finally, Leerink Partners upgraded shares of Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 price target on the stock in a report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $203.08.

Spruce Biosciences Stock Up 0.8%

Shares of NASDAQ SPRB opened at $84.42 on Wednesday. The stock has a market cap of $90.33 million, a P/E ratio of -0.99 and a beta of 3.45. The firm’s 50-day simple moving average is $104.27 and its 200 day simple moving average is $50.86. Spruce Biosciences has a fifty-two week low of $4.28 and a fifty-two week high of $240.00.

Institutional Trading of Spruce Biosciences

An institutional investor recently bought a new position in Spruce Biosciences stock. Cable Car Capital LP acquired a new stake in Spruce Biosciences, Inc. (NASDAQ:SPRB) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 26,666 shares of the company’s stock, valued at approximately $239,000. Cable Car Capital LP owned 5.33% of Spruce Biosciences as of its most recent filing with the SEC. Institutional investors and hedge funds own 91.71% of the company’s stock.

Key Spruce Biosciences News

Here are the key news stories impacting Spruce Biosciences this week:

• Positive Sentiment: Oppenheimer initiated coverage with an “Outperform,” providing fresh institutional buy-side interest that can lift demand for the shares. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” and maintains a $220 price target — a bullish signal given that the target is well above current trading levels and may fuel momentum and retail/institutional interest. Read More.
• Neutral Sentiment: Short-interest report shows 0 shares and inconsistent/NaN changes, indicating no clear short-position pressure or that the data is unreliable — this neither supports a large short squeeze thesis nor signals heavy short-selling at present.
• Negative Sentiment: HC Wainwright’s published quarterly and annual EPS forecasts imply substantial losses (examples include FY2025 and FY2026 negatives and quarterly EPS deeply below zero). Those projected multi-period losses highlight significant cash burn and execution/approval risk that could limit upside unless clinical or commercial progress materializes.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.